Poll Results: Use of Rivaroxaban Post-ACS

In our most recent poll, we asked responders to identify for which patient groups they would consider low-dose rivaroxaban (2.5 mg BID). The most popular choice was in patients with polyvascular disease (42%) followed by patients with recurrent events while on a P2Y12 inhibitor (32%). Few responders selected patients with chronic kidney disease (CKD), diabetes mellitus (DM), or congestive heart failure (CHF) alone, but about 15% selected patients with any of the following: polyvascular disease, CKD, DM, or CHF.

Dual pathway inhibition with low-dose rivaroxaban combined with low-dose aspirin was approved by the US Food and Drug Administration based on the findings of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, which enrolled patients with coronary artery disease, peripheral artery disease, or both. In the overall population, this strategy resulted in a 24% reduction in the risk of myocardial infarction, stroke, or cardiovascular death. Subgroups with larger absolute risk reduction included those with polyvascular disease, DM, CKD, and CHF.

Poll Results: Use of Rivaroxaban Post-ACS

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Heart Failure and Cardiomyopathies, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and ACS, Acute Heart Failure

Keywords: Acute Coronary Syndrome, Coronary Artery Disease, Peripheral Arterial Disease, United States Food and Drug Administration, Myocardial Infarction, Heart Failure, Anticoagulants, Renal Insufficiency, Chronic, Diabetes Mellitus

< Back to Listings